EUCTR2008-006021-14-ES进行中（未招募）1 期
Estudio fase III, aleatorizado, doble ciego y controlado con placebo, de sorafenib más erlotinib frente a sorafenib más placebo como tratamiento sistémico de primera línea para el carcinoma hepatocelular.(A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)) - SEARCH: Sorafenib and Erlotinib, A RAndomized TRial ProtoCol for the Treatment of Patients with Hepa
Bayer HealthCare AG, 51368 Leverkusen, Germany0 个研究点目标入组 700 人开始时间: 2009年5月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Patients with histological or cytologically documented HCC or clinical diagnosis by AASLD criteria in cirrhotic subjects is required. For subjects without cirrhosis histological confirmation is necessary.
- •* Patients must have at least one tumor lesions that meets both of the following criteria:
- •- Lesion can be accurately measured in at least one dimension according to RECIST
- •- Lesion has not been previously treated with local therapy (such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation
- •* Patients who have received local therapy are eligible. Local theapy must be completed at least 4 weeks prior to the baseline scan. Previously treated lesions will not be selected as target lesions.
- •* Patients with an ECOG PS of 0 or 1.
- •* Cirrhotic status of Child-Pugh Class A.
- •* Following Laboratory Parameters (as assessed by Central Laboratory):
- •- Platelet count >= 60 x 109/L
- •- Hemoglobin >= to 8.5 g/dl
- •- Total Bilirubin =< 2.8 mg/dl
- •- ALT and AST =< 5 x ULN
- •- Serum Creatinine =< 1.5 x ULN
- •- PT international normalized ration (INR) =< 2.3 or PT =< 6 seconds above control
- •- Patients who are being therapeutically anticoagulated with an agent such as wafarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.
- •* Patients must provide written informed consent prior to any study procedures being performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •* Renal failure requiring hemo- or peritoneal dialysis
- •* Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)- related illness or serious acute or chronic illness.
- •* Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogren´s syndrome) including congenital abnormality (e.g. Fuch´s dystrophy), abnormal slit-lamp examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test).
- •* Child-Pugh class B or C
- •* Previous treatment with yttrium- 90 spheres
- •* Clinically significant peripheral vascular disease
- •* History of cardiac disease: congestive heart failure > New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted. (See Appendix 10.7)
- •* History of interstitial lung disease (ILD)
- •* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
- •* Active clinically serious infections (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 3.0), except HBV/HCV infections
- •* Uncontrolled ascites (defined as not easily controlled with diuretic treatment)
- •* Pregnant or breast-feeding patients.
研究者
相似试验
进行中（未招募）
不适用
Estudio fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia de la inmunoterapia antitumoral antígeno específica recMAGE-A3 + AS15 como tratamiento adyuvante en pacientes con cáncer de pulmón no microcítico MAGE-A3 positivo resecable.A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer - MAGE3-AS15-NSC-003Tratamiento adyuvante en pacientes con cáncer de pulmón no microcítico (CPNM) MAGE-A3 positivo y que se les ha practicado una resección quirúrgica completa.Adjuvant therapy in patients with MAGE-A3-positive Non-Small Cell Lung Cancer (NSCLC) and who have had complete surgical resection.EUCTR2007-001283-73-ESGlaxoSmithKline, S.A.2,270
进行中（未招募）
不适用
Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a (Pegasys®) y ribavirina (Copegus®) o peginterferón alfa-2b (PegIntron®) y ribavirina (Rebetol®) en sujetos infectados por el virus de la hepatitis C, genotipo 1, no tratados previamente.A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve, genotype 1, hepatitis C-infected subjects. - Quest 2Hepatitis C Virus (HCV) in treatment naïve patientsInfección por el virus de la hepatitis C (VHC) en pacientes que no han recibido nunca tratmientoMedDRA version: 12.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)EUCTR2010-021174-11-ESTibotec Pharmaceuticals375
进行中（未招募）
1 期
Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a y ribavirina en pacientes infectados por el virus de la hepatitis C, genotipo 1, no tratados previamente. - Quest 1EUCTR2010-020444-36-ESTibotec Pharmaceuticals
进行中（未招募）
1 期
Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterferón alfa-2a y ribavirina en sujetos infectados por el genotipo 1 de la hepatitis C que han recidivado tras un tratamiento previo basado en interferón A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy - PromiseHepatitis C Virus (HCV)MedDRA version: 12.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)EUCTR2010-021113-23-ESTibotec Pharmaceuticals
进行中（未招募）
1 期
Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de AST-120 para la prevención de la progresión de la Enfermedad Renal Crónica en pacientes con Enfermedad Renal Crónica moderada o grave que incluirá la valoración de la calidad de vidaEUCTR2005-004990-13-ESKureha Corporation800